Lynk Pharmaceuticals Co., Ltd. has completed patient enrollment in a Phase III clinical trial evaluating zemprocitinib capsules in adults with active ankylosing spondylitis. The company said enrollment was completed on July 9, 2026, with 352 patients entering the randomized study, although no Phase III efficacy or safety results have yet been reported.
The milestone removes the recruitment uncertainty that can delay late-stage clinical programmes and establishes a clearer path toward primary endpoint analysis. It does not, however, demonstrate that zemprocitinib is effective, safer than other Janus kinase inhibitors or ready for regulatory approval.
Zemprocitinib, previously identified as LNK01001, is an investigational oral, selective Janus kinase 1 inhibitor. Lynk Pharmaceuticals is developing the drug across several immune-mediated diseases, including ankylosing spondylitis, rheumatoid arthritis, atopic dermatitis and vitiligo. Its atopic dermatitis application is already under review in China, while the company has reported positive Phase III topline findings in rheumatoid arthritis.
The ankylosing spondylitis programme now becomes an important test of whether zemprocitinib’s clinical profile can extend across a third major inflammatory indication. Each indication must nevertheless stand on its own evidence, and success in rheumatoid arthritis or atopic dermatitis cannot predict the outcome of the ankylosing spondylitis trial.
Why is the 352-patient enrollment milestone operationally important but not yet a clinical result?
The Phase III study, registered as NCT07237568 and CTR20233855, is a multicentre, randomized, double-blind, parallel-group and placebo-controlled trial. During the initial 16-week period, participants are assigned in a one-to-one ratio to receive either zemprocitinib 12 mg orally twice daily or matching placebo.
Patients initially assigned to placebo are expected to switch to zemprocitinib after Week 16, creating a 36-week open-label extension and a total planned treatment period of 52 weeks. This structure provides a controlled assessment of efficacy through Week 16 while allowing the company to gather longer-duration exposure and safety information after the placebo-controlled period ends.
Eligible participants have an established diagnosis of ankylosing spondylitis and active disease despite prior treatment. Registered criteria include a Bath Ankylosing Spondylitis Disease Activity Index score of at least four and a total back-pain score of at least four, indicating a population with clinically meaningful ongoing symptoms.
Completing enrollment means Lynk Pharmaceuticals can now focus on treatment completion, follow-up, data cleaning and statistical analysis. Recruitment risk has fallen, but clinical risk remains. Attrition, missing data, treatment discontinuations, protocol deviations and the eventual separation from placebo will still influence the strength of the evidence package.
What must the Week 16 ASAS40 endpoint establish in active ankylosing spondylitis?
The primary endpoint is the proportion of patients achieving an Assessment of SpondyloArthritis International Society 40 response at Week 16. ASAS40 is a composite measure requiring substantial improvement across important disease domains, including pain, physical function, inflammation and a patient’s overall assessment of disease activity.
The endpoint is more demanding than a 20 percent response threshold and is commonly used in pivotal ankylosing spondylitis studies. A statistically significant difference from placebo would provide evidence that zemprocitinib improves the signs and symptoms of active disease over the controlled treatment period.
The magnitude of that difference will matter alongside the statistical result. A study can meet its primary endpoint while producing an effect that clinicians or payers consider insufficiently differentiated from existing treatments. The response rate, placebo-adjusted benefit, consistency across secondary endpoints and performance in relevant patient subgroups will therefore require close examination.
ASAS40 also does not directly demonstrate that a treatment prevents structural spinal damage or changes the long-term course of ankylosing spondylitis. The Phase III programme can establish symptomatic and functional benefit, but claims concerning disease modification would require appropriate imaging, longer follow-up and supporting clinical evidence.
Secondary measures involving disease activity, function, quality of life and lower response thresholds should help determine whether any primary endpoint benefit is broad and internally consistent. Regulators will also examine how missing observations and treatment discontinuations were handled in the statistical analysis.
How strongly do Phase II results support the 12 mg zemprocitinib dose selected for Phase III?
The Phase III programme is supported by a completed 177-patient Phase II study conducted across 21 sites in China. Participants were randomized to receive zemprocitinib 12 mg twice daily, 24 mg twice daily or placebo for 12 weeks.
Lynk Pharmaceuticals reported that 27.6 percent of patients in the 12 mg group achieved an ASAS40 response at Week 12, compared with 11.7 percent in the placebo group. The 24 mg group produced a higher response rate of 35.6 percent. Both dose groups met the Phase II primary endpoint against placebo, according to the company’s clinical disclosures.
The lower dose did not produce uniformly stronger results across every measure. The reported ASAS20 response was 43.1 percent with 12 mg and 26.7 percent with placebo, with a p-value of 0.06. The 24 mg group recorded a 59.3 percent ASAS20 response, which was statistically significant against placebo. Other reported measures, including ASAS5/6, disease activity, physical function and quality of life, supported biological and clinical activity.
Lynk Pharmaceuticals subsequently chose 12 mg twice daily for Phase III after reviewing the broader efficacy and safety experience generated in rheumatoid arthritis and atopic dermatitis. The company’s Hong Kong listing application indicated that the Center for Drug Evaluation agreed in July 2025 that the ankylosing spondylitis trial could proceed with this adjusted regimen.
That decision makes the confirmatory study particularly consequential. Phase III must demonstrate that the lower dose preserves sufficient efficacy in a larger population while providing an appropriate benefit-risk profile. The study does not include a 24 mg arm, so it will not directly establish whether the selected regimen offers the best balance among the doses previously tested.
Can greater JAK1 selectivity translate into a clinically differentiated safety profile?
Zemprocitinib was designed to inhibit JAK1-mediated inflammatory signalling while limiting activity against other Janus kinase family members, particularly JAK2 and JAK3. In theory, greater target selectivity could reduce unwanted effects associated with inhibiting pathways involved in blood-cell formation and other physiological functions.
That molecular rationale remains different from a demonstrated clinical safety advantage. In vitro selectivity does not establish that a drug will produce fewer serious infections, cardiovascular events, thromboembolic events, malignancies or laboratory abnormalities in treated patients.
The Phase II ankylosing spondylitis study provided an encouraging but limited safety signal. Lynk Pharmaceuticals reported low rates of serious adverse events, Grade 3 or higher treatment-emergent adverse events and treatment discontinuations over 12 weeks. No serious infections, major adverse cardiovascular events, thrombotic events or malignancies were reported across the study groups.
The sample size and treatment duration were too limited to exclude uncommon or delayed risks. Safety scrutiny is especially important because regulators in major markets have applied class-level warnings and risk-management measures to approved JAK inhibitors used for chronic inflammatory diseases.
Lynk Pharmaceuticals has also reported favourable safety and tolerability findings from longer Phase III studies in rheumatoid arthritis and atopic dermatitis. Those datasets broaden exposure to zemprocitinib, but detailed results, patient risk characteristics and event rates will remain important. Regulators may examine pooled evidence across indications while still assessing whether ankylosing spondylitis patients present different baseline risks.
The 36-week extension should add valuable cumulative exposure. Clinicians and regulators will watch serious infections, herpes zoster, malignancies, cardiovascular events, thrombosis, blood-cell changes, liver enzymes, lipids and treatment discontinuations. The absence of a signal in a short controlled period would not by itself establish a superior long-term safety profile.
Why will oral administration alone not secure zemprocitinib a place in China’s treatment market?
Treatment for active ankylosing spondylitis generally begins with non-steroidal anti-inflammatory drugs alongside exercise and physical management. Patients who remain active may progress to targeted therapies, including tumour necrosis factor inhibitors, interleukin-17 inhibitors and oral JAK inhibitors.
An oral small molecule may offer practical advantages for patients who prefer tablets to injections or infusions. It can also simplify storage and administration compared with some biologic therapies. Zemprocitinib’s twice-daily regimen, however, will still need to demonstrate that its efficacy, tolerability and convenience justify its use within an increasingly competitive field.
China already has approved oral JAK options for ankylosing spondylitis, including upadacitinib, tofacitinib and ivarmacitinib. Zemprocitinib therefore would not enter an empty category. It would compete with established biologics, biosimilars and other small molecules with existing regulatory, reimbursement and physician-use experience.
Lynk Pharmaceuticals has not conducted a head-to-head ankylosing spondylitis trial against an approved JAK inhibitor or biologic. Comparisons based on response percentages from separate trials would be unreliable because patient populations, prior treatment exposure, endpoint timing, background therapy and statistical methods can differ materially.
Commercial differentiation will consequently depend on the total evidence package. Efficacy magnitude, onset of response, durability, safety, monitoring requirements, pricing, reimbursement and access will be more important than oral administration by itself.
How will Simcere Pharmaceutical Group influence zemprocitinib’s commercial execution?
Lynk Pharmaceuticals has granted Jiangsu Simcere Pharmaceutical Co., Ltd., part of Simcere Pharmaceutical Group Limited, exclusive commercialization rights for zemprocitinib in rheumatoid arthritis and ankylosing spondylitis across Chinese Mainland, Hong Kong, Macau and Taiwan.
Simcere Pharmaceutical Group contributes an established distribution network and a rheumatology-focused commercial organisation. It is also providing services connected with Phase III development, regulatory documentation, vendor coordination and preparation for potential new drug applications. Lynk Pharmaceuticals remains the clinical trial sponsor and retains responsibility for development, regulatory strategy, manufacturing and product supply.
The arrangement reduces the need for Lynk Pharmaceuticals to build a large specialist sales infrastructure before launch. It also creates execution interdependence. Approval would need to be followed by reliable manufacturing, appropriately timed supply, competitive pricing, physician education and reimbursement access.
The parties’ agreement calls for commercially reasonable efforts to secure marketing authorizations for ankylosing spondylitis and rheumatoid arthritis by the end of 2027. That contractual target is not a regulatory guarantee. The timing will depend on trial results, dossier completeness, regulatory review and whether additional analyses or studies are requested.
What does the enrollment milestone mean for Lynk Pharmaceuticals’ proposed Hong Kong listing?
Lynk Pharmaceuticals submitted a draft application for a Hong Kong listing under the framework used by pre-revenue biotechnology companies in June 2026. The company had not completed the listing or begun public trading when the ankylosing spondylitis enrollment announcement was issued.
The completion of Phase III enrollment strengthens the company’s development-execution narrative because recruitment is no longer an open-ended variable. It also moves a core product toward another potentially registrational dataset at a time when zemprocitinib already has an atopic dermatitis application under Chinese regulatory review.
The milestone should not be treated as clinical de-risking equivalent to a successful Phase III result. Zemprocitinib remains investigational for ankylosing spondylitis, and the value of the programme will depend heavily on the eventual ASAS40 result, safety profile and regulatory response.
Lynk Pharmaceuticals reported no revenue in 2024 or 2025. It recorded RMB38.6 million of revenue during the first quarter of 2026, generated from a separate out-licensing arrangement, while research and development expenditure reached RMB158.4 million in 2025. The company reported RMB144.1 million in cash and cash equivalents and RMB50 million in term deposits at the end of March 2026.
Those figures underline why late-stage execution and access to capital remain commercially relevant. Zemprocitinib spans multiple indications, but every additional Phase III programme, regulatory filing and manufacturing preparation step requires funding before meaningful product revenue can begin.
Which milestones will determine whether zemprocitinib advances toward an ankylosing spondylitis filing?
The first decisive event will be the Week 16 primary analysis after the last enrolled patients complete the placebo-controlled treatment period and the database is prepared for analysis. Lynk Pharmaceuticals has not announced a firm date for releasing topline ankylosing spondylitis results.
Attention will then shift to the ASAS40 effect size, secondary endpoints, discontinuations and the balance of adverse events between zemprocitinib and placebo. The 52-week dataset will be important for evaluating response durability and accumulating the longer-term safety information required for a chronic treatment.
Lynk Pharmaceuticals’ June 2026 listing application indicated that it planned to complete the ankylosing spondylitis Phase III programme and submit a Chinese new drug application during the second half of 2027. That remains a company target rather than a confirmed regulatory timetable.
Enrollment has moved zemprocitinib into the execution-heavy final stage of its ankylosing spondylitis trial. The programme’s credibility will now be determined not by the number of recruited patients, but by whether the selected 12 mg regimen delivers a convincing Week 16 benefit, a sufficiently durable response and a safety profile capable of supporting regulatory review in an already competitive JAK inhibitor market.
